Article
Oncology
A. Bamias, A. S. Merseburger, Y. Loriot, N. James, E. Choy, D. Castellano, F. Lopez-Rios, F. Calabro, M. Kramer, G. de Velasco, R. Zakopoulou, K. Tzannis, C. N. Sternberg
Summary: This study examined the impact of pretreatment factors on the efficacy of atezolizumab in platinum-refractory advanced urothelial cancer. The results showed significant associations between Bellmunt risk factors, TFLC, PD-L1 expression, and previous therapy with overall survival. The study highlighted the importance of novel prognostic signatures for immunotherapy-treated patients with aUC.
Article
Oncology
Joaquim Bellmunt, Maha Hussain, Jurgen E. Gschwend, Peter Albers, Stephane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H. O'Donnell, Jonathan E. Rosenberg, Daniel M. Geynisman, Daniel P. Petrylak, Jean Hoffman-Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S. van der Heijden, Cora N. Sternberg, Nicole N. Davarpanah, Thomas Powles
Summary: IMvigor010 is the largest adjuvant study evaluating a checkpoint inhibitor in muscle-invasive urothelial carcinoma. The trial did not show improved disease-free survival with atezolizumab compared to observation. Atezolizumab was generally well tolerated, but higher rates of adverse events leading to discontinuation were reported compared to previous studies on metastatic urothelial carcinoma.
Article
Oncology
Deniz Tural, Omer Fatih Olmez, Ahmet Taner Sumbul, Nail Ozhan, Burcu Cakar, Osman Kostek, Meltem Ekenel, Mustafa Erman, Hasan Senol Coskun, Fatih Selcukbiricik, Ozge Keskin, Fatma Paksoy Turkoz, Kerem Oruc, Selami Bayram, Irem Bilgetekin, Birol Yildiz, Mehmet Ali Nahit Sendur, Nail Paksoy, Ahmet Dirican, Dilek Erdem, Meltem Selam, Ozgur Tanriverdi, Semra Paydas, Zuhat Urakci, Elif Atag, Sabri Guncan, Yuksel Urun, Ali Alkan, Ali Osman Kaya, Deniz Tataroglu Ozyukseler, Halil Taskaynatan, Mustafa Yildirim, Muge Sonmez, Tugba Basoglu, Seyda Gunduz, Saadettin Kilickap, Mehmet Artac
Summary: The study evaluated pretreatment prognostic factors for overall survival in metastatic urothelial carcinoma patients who have progressed after first-line chemotherapy with Atezolizumab. Factors such as liver metastases, ECOG performance status, and hemoglobin levels were found to be significantly associated with overall survival, providing insights for clinical trials using immunotherapy in bladder cancer patients.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Jiekun Qian, Zhangwei Tong, Yannan Zhang, Chun Chen
Summary: This study aims to compare the efficacy of single immunotherapy and traditional platinum-based chemotherapy in thymic carcinoma patients, providing a basis for clinicians to establish the best treatment regimen and offering research clues for clinical researchers in the field.
Article
Urology & Nephrology
Deniz Tural, Omer Fatih Olmez, Ahmet Taner Sumbul, Mehmet Artac, Nail Ozhan, Emre Akar, Burcu Cakar, Osman Kostek, Meltem Ekenel, Mustafa Erman, Hasan Senol Coskun, Fatih Selcukbiricik, Ozge Keskin, Fatma Paksoy Turkoz, Kerem Oruc, Selami Bayram, Ugur Yglmaz, Irem Bilgetekin, Birol Ygldgz, Mehmet Ali Nahit Sendur, Nail Paksoy, Ahmet Dirican, Dilek Erdem, Meltem Selam, Ozgur Tanrgverdi, Semra Paydas, Zuhat Urakcg, Elif Atag, Sabri Guncan, Yuksel Urun, Ali Alkan, Ali Osman Kaya, Deniz Tataroglu Ozyukseler, Halil Taskaynatan, Mustafa Ygldgrgm, Muge Sonmez, Tugba Basoglu, Seyda Gunduz, Saadettin Kglgckap
Summary: This study analyzed data from 115 patients with metastatic bladder cancer treated with atezolizumab, finding it to be effective and well tolerated in patients who had progressed with previous treatment. Despite some limitations, the results are consistent with previous clinical trial outcomes.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Oncology
Amit G. Singal, Kirhan Ozgurdal, Xiaozhou Fan, Zdravko Vassilev, Xiaoyun Pan, Jasjit K. Multani, Chi-Chang Chen, Zifan Zhou, Jing He, Federica Pisa
Summary: This retrospective cohort study evaluated the treatment patterns of atezolizumab plus bevacizumab (atezo + bev) for hepatocellular carcinoma in clinical practice. The study found that most patients discontinued atezo + bev and only a minority received subsequent therapies.
Article
Multidisciplinary Sciences
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Akira Doi, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Masanori Miyazaki, Takayuki Yakushijin, Yasutoshi Nozaki, Kengo Matsumoto, Satoshi Tanaka, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Yukinori Yamada, Naoki Morishita, Takeo Usui, Naoki Hiramatsu, Yoshinori Doi, Mitsuru Sakakibara, Kazuho Imanaka, Yuichi Yoshida, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Summary: This study aimed to assess the impact of antibiotic use on therapeutic response in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab. The results showed that prior antibiotic use was associated with reduced therapeutic responses.
Article
Oncology
Omar Alhalabi, Yueting Zhu, Ameer Hamza, Wei Qiao, Yiyun Lin, Raymond M. Wang, Amishi Y. Shah, Matthew T. Campbell, Vijaykumar Holla, Ashish Kamat, Wei-Lien Wang, Jennifer Wang, Jianfeng Chen, Jieru Meng, Miao Zhang, Jolanta Bondaruk, Mark Titus, Giannicola Genovese, Bogdan A. Czerniak, Kenna R. Shaw, Funda Meric-Bernstam, Charles C. Guo, Christopher J. Logothetis, Arlene Siefker-Radtke, Pavlos Msaouel, Linghua Wang, Jiyan Liu, Jianjun Gao
Summary: The deficiency of MTAP is mainly caused by the loss of both alleles of chromosome 9p21, which is the most common copy-number loss in metastatic urothelial cancer (mUC). Clinical and genomic features of MTAP(def) mUC were investigated in 193 patients at MD Anderson Cancer Center (MDACC) and 298 patients in the phase 2 IMvigor210 trial. The results showed that MTAP(def) was associated with more frequent visceral metastases and poor prognosis. The study also found distinct gene mutations in MTAP(def) tumors, suggesting a different biology in MTAP(def) mUC.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Article
Oncology
M. Ferreiro-Pantin, U. Anido-Herranz, Y. Z. Betancor, V. Cebey-Lopez, L. Leon-Mateos, J. Garcia-Gonzalez, S. M. Garcia-Acuna, N. Fernandez-Diaz, J. M. C. Tubio, R. Lopez-Lopez, J. Ruiz-Banobre
Summary: This study validates the Immunotherapy Response Score (IRS) as a strong independent prognostic and predictive biomarker for overall survival (OS) and disease control/response in patients with advanced urothelial carcinoma (aUC) treated with atezolizumab monotherapy in the IMvigor210 phase II clinical trial.
Article
Oncology
Nicholas H. Chakiryan, Da David Jiang, Kyle A. Gillis, Elizabeth Green, Ali Hajiran, Lee Hugar, Logan Zemp, Jingsong Zhang, Rohit Jain, Jad Chahoud, Roger Li, Wade Sexton, Brandon J. Manley, Scott M. Gilbert
Summary: This retrospective study compared the overall survival (OS) between first-line immunotherapy and chemotherapy in patients with metastatic bladder urothelial carcinoma. The findings suggest that there is no significant difference in OS between the two treatments.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Oncology
Cedric Brackenier, Lisa Kinget, Sarah Cappuyns, Chris Verslype, Benoit Beuselinck, Jeroen Dekervel
Summary: Hepatocellular carcinoma (HCC) is a prevalent cancer with a high mortality rate. The combination of an antiangiogenic drug and an immune checkpoint inhibitor has become the new standard of care for advanced HCC. This review discusses the mode of action, clinical efficacy, and biomarker research for both drug classes and the combination therapy. It also highlights the synergy between the two drugs and provides insights into the underlying immunoreactive tumor microenvironment.
Article
Urology & Nephrology
Taizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Takeshi Hashimoto, Atsuhiko Yoshizawa, Ko Nakamura, Yusuke Yano, Kazuki Nishimura, Kyosuke Nishio, Keita Nakamori, Kosuke Iwatani, Shutaro Yamamoto, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Shin Egawa, Haruhito Azuma
Summary: This study assessed the clinical benefit of re-challenging chemotherapy after pembrolizumab in patients with metastatic urothelial carcinoma (mUC). The results showed that re-challenging chemotherapy, including platinum agents, offered clinical benefits in patients with mUC who experienced progressive disease (PD) after pembrolizumab treatment.
Article
Oncology
Shiyong Xin, Ruixin Li, Junjie Su, Qiong Cao, Haojie Wang, Zhihao Wei, Guanyu Li, Wang Qin, Zheng Zhang, Chengliang Wang, Chengdong Zhang, Jianguo Zhang
Summary: This study investigates the potential role of disulfidptosis-related genes in bladder urothelial carcinoma (BLCA) and their involvement in immune cell infiltration. The findings reveal the importance of disulfidptosis in BLCA and its potential regulatory mechanisms.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Guru P. Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, Xiao X. Wei, Kerry L. Kilbridge, Richard J. Lee, Evan Y. Yu, Michael Thomas Schweizer, Robert B. Montgomery, Heather H. Cheng, Andrew Caleb Hsieh, Rohit Jain, Jaspreet S. Grewal, Cesar Pico-Navarro, Zarina Gafoor, Teresa Perschy, Petros Grivas
Summary: This study evaluated the combination of CV301 and atezolizumab as a treatment for cisplatin-ineligible advanced urothelial carcinoma and highlighted the challenges in vaccine development.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Biotechnology & Applied Microbiology
Rodney P. Rocconi, Erin E. Stevens, Justin N. Bottsford-Miller, Sharad A. Ghamande, Jeffrey Elder, Leslie L. DeMars, Adnan Munkarah, Phylicia Aaron, Laura Stanbery, Gladice Wallraven, Ernest Bognar, Meghan Manley, Staci Horvath, Luisa Manning, Adam Walter, Evanthia Galanis, Thomas Herzog, Bradley J. Monk, Robert L. Coleman, John Nemunaitis
Summary: The study investigated the safety and efficacy of the personalized vaccine Vigil in combination with atezolizumab in relapsed ovarian cancer patients. Results showed that the Vigil-1st combination therapy with atezolizumab was safe and effective, supporting further investigation in patients with BRCA(wt).
CANCER GENE THERAPY
(2022)
Letter
Urology & Nephrology
Giuseppe Basile, Marco Bandini, Francesco Montorsi, Andrea Necchi
Article
Oncology
Sean M. Hacking, Dean Pavlick, Yihong Wang, Benedito A. Carneiro, Matthew Mullally, Shaolei Lu, Mariana Canepa, Gennady Bratslavsky, Joseph Jacob, Andrea Necchi, Philippe E. Spiess, Li Wang, Evgeny Yakirevich, Jeffrey Ross
Summary: Comprehensive genomic profiling (CGP) was used to evaluate the frequency of NF2 genomic alterations in histologic subtypes of kidney tumors and co-occurring genomic alterations in other genes and biomarkers. The study found that NF2 mutations were more frequent in collecting duct carcinoma, sarcomatoid carcinoma, papillary carcinoma, and unclassified carcinoma, while less frequent in clear cell carcinoma, urothelial carcinoma of renal pelvis, and Wilms tumor. NF2-mutant RCC also exhibited co-occurring genetic alterations in CDKN2A/B, SETD2, and BAP1, which could potentially serve as therapeutic targets. Moreover, the higher level of PD-L1 expression in NF2-mutant tumors suggests that these tumors might be sensitive to immune checkpoint inhibitor therapies.
Article
Oncology
Taylor Peak, Philippe E. Spiess, Roger Li, Petros Grivas, Andrea Necchi, Dean Pavlick, Richard S. P. Huang, Douglas Lin, Natalie Danziger, Joseph M. Jacob, Gennady Bratslavsky, Jeffrey S. Ross
Summary: Although UCB rates are low in South Asian and East Asian patients, they represent a significant proportion globally. However, these patients are under-represented in clinical trials. This study provides important insights into the genomic landscape of UCB in East and South Asian patients, highlighting the need for more diverse inclusion in clinical trials.
Article
Oncology
Karim Fizazi, Neal D. Shore, Matthew Smith, Rodrigo Ramos, Robert Jones, Guenter Niegisch, Egils Vjaters, Yuan Wang, Shankar Srinivasan, Toni Sarapohja, Frank Verholen
Summary: Darolutamide significantly improved the survival rate of nmCRPC patients and showed a favorable safety profile during the treatment.
EUROPEAN JOURNAL OF CANCER
(2023)
Meeting Abstract
Urology & Nephrology
Kyle Rose, Marco Bandini, Heather Huelster, Giuseppe Basile, Shreyas Naidu, Philippe Spiess, Andrea Necchi, Roger Li
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Giuseppe Rosiello, Chiara Re, Francesco Cei, Giuseppe Basile, Giacomo Musso, Giuseppe Fallara, Federico Belladelli, Daniele Cignoli, Daniela Canibus, Silvia Patricia Soares Pinto, Andrea Necchi, Laura Marandino, Pierre I. Karakiewicz, Isaline Rowe, Giulia Villa, Mattia Boarin, Natasha Disabato, Francesco Trevisani, Arianna Bettiga, Alberto Briganti, Francesco Montorsi, Andrea Salonia, Alessandro Larcher, Umberto Capitanio
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Antony Pellegrino, Elio Mazzone, Giorgio Gandaglia, Andrea Necchi, Daniele Raggi, Laura Marandino, Armando Stabile, Vito Cucchiara, Marco Bandini, Giuseppe Rosiello, Gabriele Sorce, Francesco Pellegrino, Simone Scuderi, Daniele Robesti, Mario de Angelis, Mattia Longoni, Pietro Scilipoti, Francesco Montorsi, Alberto Briganti
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Giuseppe Basile, Giorgio Brambilla, Marco Bandini, Daniele Raggi, Laura Marandino, Tiago Costa De Padua, Emanuele Crupi, Renzo Colombo, Maurizio Colecchia, Roberta Luciano, Marco Moschini, Jeffrey S. Ross, Alberto Briganti, Francesco Montorsi, Francesco De Cobelli, Andrea Necchi
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Federico Belladelli, Chiara Re, Francesco Cei, Lucia Salerno, Sara Cusano, Floriana Iannace, Paola Carrera, Maria Grazia Patricelli, Andrea Falini, Francesco De Cobelli, Pietro Mortini, Francesco Bandello, Rosangela Lattanzio, Massimo Falconi, Stefano Partelli, Andrea Necchi, Daniele Raggi, Laura Marandino, Roberta Luciano, Isaline Rowe, Irene Franco, Francesco Montorsi, Umberto Capitanio, Alessandro Larcher, Andrea Salonia
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Daniele Cignoli, Alessandro Bandiera, Giuseppe Fallara, Giuseppe Rosiello, Giuseppe Basile, Gianmarco Colandrea, Gianfranco Baiamonte, Francesco Cei, Giacomo Musso, Francesco De Cobelli, Giorgio Brembilla, Daniela Canibus, Roberto Bertini, Francesco Montorsi, Laura Marandino, Daniele Raggi, Andrea Salonia, Alberto Briganti, Giampiero Negri, Vanesa Gregorc, Andrea Necchi, Alessandro Larcher, Umberto Capitanio
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Siamak Daneshmand, Michiel S. van der Heijden, Joseph M. Jacob, Andrea Necchi, Evanguelos Xylinas, David S. Morris, Philip Spiegelhalder, Daniel Zainfeld, Taek Won Kang, Justin T. Matulay, Laurence H. Belkoff, Karel Decaestecker, Harm Arentsen, Shalaka Hampras, Shu Jin, Christopher J. Cutie, Hussein Sweiti, Katherine Stromberg, Jason Martin, Giuseppe Simone
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
C. Re, F. Belladelli, F. Cei, L. Salerno, S. Cusano, F. Innace, G. B. Pipitone, P. Carrera, Russo A. Raucci, M. G. Patricelli, A. Falini, F. De Cobelli, P. Mortini, F. Bandello, R. Lattanzio, M. Falconi, S. Partelli, A. Necchi, L. Marandino, I Rowe, F. Montorsi, U. Capitanio, A. Larcher, A. Salonia
Meeting Abstract
Urology & Nephrology
D. Robesti, L. Nocera, F. Belladelli, J. G. Schultz, G. Fallara, L. Marandino, D. Raggi, F. Montorsi, A. Necchi, A. Martini
Article
Urology & Nephrology
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesus Garcia-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begona Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot
Summary: This study aimed to understand and manage the treatment-emergent adverse events (TEAEs) of Erdafitinib to optimize fibroblast growth factor receptor inhibitor (FGFRi) treatment. The results showed that early identification and proactive management of select TEAEs can improve or resolve most adverse events in patients, allowing for maximum benefit from FGFRi treatment.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Article
Urology & Nephrology
Arash Rezazadeh Kalebasty, David J. Benjamin, Yohann Loriot, Dimitrios Papantoniou, Arlene O. Siefker-Radtke, Andrea Necchi, Vahid Naini, Jenna Cody Carcione, Ademi Santiago-Walker, Spyros Triantos, Earle F. Burgess
Summary: This study analyzed the clinical outcomes of patients with locally advanced or metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa+) who received anti-PD-(L)1 therapy, and found that FGFRa+ patients may have poorer outcomes compared to FGFRa- patients.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)